Don’t Leave the Door Open
Is a small spike in endophthalmitis events with Eylea nothing more than a refrigeration issue – or something more?
Mark Hillen |
Endophthalmitis is a nightmare for ophthalmologists; sometimes you can treat it, sometimes you lose the eye. But when you go into the eye to perform surgery – or even inject a drug – there’s always a risk that infection can occur. But even then, with precautions, the risk of endophthalmitis is miniscule. After all, the most commonly performed surgery (of all of medicine, not just ophthalmology) is cataract surgery, and people receive intravitreal injections as a matter of routine.
However, it appears that no one can fully relax. On February 21, Bloomberg published an article with a troubling first sentence: “Doctors say they’re seeing an unexplained increase in a rare, frightening side effect in patients getting Regeneron Pharmaceuticals Inc’s top-selling product, the blockbuster eye drug Eylea” (1). So what’s the story?
Read the full article now
Log in or register to read this article in full and gain access to The Ophthalmologist’s entire content archive. It’s FREE and always will be!
Or register now - it’s free and always will be!
You will benefit from:
- Unlimited access to ALL articles
- News, interviews & opinions from leading industry experts
- Receive print (and PDF) copies of The Ophthalmologist magazine
Or Login via Social Media
By clicking on any of the above social media links, you are agreeing to our Privacy Notice.